Search
Bioatla Inc
BCABAdd to Watchlist
3.640USD
+0.090+2.54%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
120.82KMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Bioatla Inc is 10.00, ranking 1 out of 388 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
10.000
Target Price
+6427.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Bioatla Inc
BCAB
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Bioatla Inc's price target?
Analysts forecast that Bioatla Inc's price target is USD 10.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 10.00.
How have Bioatla IncBCAB's recent earnings per share performed?
The market expectation was USD -211.23, while Bioatla IncBCAB's earnings per share (EPS) for the previous quarter was USD -8.18. EPS for the next quarter is expected at USD -0.17.
What is the analyst rating for Bioatla Inc?
Based on the ratings of Bioatla Inc's stock from 1 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
